InsidersTradesSigma
Follow the GeoVax Labs, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Health Care sector, GeoVax Labs, Inc. has recorded 21 reports. Market capitalisation: €5.2m. The latest transaction was disclosed on 20 October 2025 (Acquisition). Among the most active insiders: McKee Kelly T. Jr.. Every trade is free.
21
Insider Decl.
n/a
Thresholds
€148,123
21 ops.
Buy Volume
n/a
n/a
Sell Volume
60Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 20 October 2025
Declarations21 total
10,000 shares@ US$0.549835.1% of flowCommon StockSEC:0001437749-25-031314:0
Canonical exit: 15 Jan 2026 (T+90)
1,107 shares@ US$0.672.8% of flowCommon StockSEC:0001437749-25-025690:0
Canonical exit: 5 Nov 2025 (T+90)
10,000 shares@ US$0.98100.0% of flowCommon StockSEC:0001437749-25-011750:0
Canonical exit: 9 Jul 2025 (T+90)
6,000 shares@ US$0.9987.1% of flowCommon StockSEC:0001437749-25-011658:0
Canonical exit: 9 Jul 2025 (T+90)
10,000 shares@ US$1.0816.0% of flowCommon StockSEC:0001437749-25-010482:0
Canonical exit: 30 Jun 2025 (T+90)
6,800 shares@ US$1.079931.9% of flowCommon StockSEC:0001437749-25-010179:0
Canonical exit: 29 Jun 2025 (T+90)
8,000 shares@ US$1.9522.9% of flowCommon StockSEC:0001437749-24-025953:0
Canonical exit: 7 Nov 2024 (T+90)
520 shares@ US$2.151.7% of flowCommon StockSEC:0001437749-24-005209:0
Canonical exit: 21 May 2024 (T+90)
2,000 shares@ US$2.7724.2% of flowCommon StockSEC:0001437749-24-003380:0
Canonical exit: 7 May 2024 (T+90)
6,944 shares@ US$0.3610.5% of flowCommon StockSEC:0001437749-23-035306:0
Canonical exit: 21 Mar 2024 (T+90)
9,653 shares@ US$0.5224.4% of flowCommon StockSEC:0001437749-23-026935:0
Canonical exit: 24 Dec 2023 (T+90)
35,087 shares@ US$0.5729.7% of flowCommon StockSEC:0001437749-23-024763:0
Canonical exit: 23 Nov 2023 (T+90)
10,000 shares@ US$0.517922.4% of flowCommon StockSEC:0001437749-23-024227:0
Canonical exit: 16 Nov 2023 (T+90)
32,000 shares@ US$0.638929.7% of flowCommon StockSEC:0001437749-23-011000:0
Canonical exit: 23 Jul 2023 (T+90)
8,000 shares@ US$0.6321.6% of flowCommon StockSEC:0001437749-23-010776:0
Canonical exit: 19 Jul 2023 (T+90)
10,000 shares@ US$1.1049.3% of flowCommon StockSEC:0001437749-22-022942:0
Canonical exit: 20 Dec 2022 (T+90)
1,000 shares@ US$0.8212.9% of flowCommon StockSEC:0001437749-22-016567:0
Canonical exit: 29 Sept 2022 (T+90)
4,464 shares@ US$1.120.062% mcap32.1% of flowCommon StockSEC:0001437749-22-016072:0
Canonical exit: 25 Sept 2022 (T+90)
10,000 shares@ US$1.210.15% mcap100.0% of flowCommon StockSEC:0001437749-22-015552:0
Canonical exit: 19 Sept 2022 (T+90)
9,722 shares@ US$0.720.087% mcap45.2% of flowCommon StockSEC:0001437749-22-011257:0
Canonical exit: 3 Aug 2022 (T+90)
4,999 shares@ US$0.710.044% mcap22.7% of flowCommon StockSEC:0001437749-22-011137:0
Canonical exit: 2 Aug 2022 (T+90)
21 of 21 declarations
About GeoVax Labs, Inc.
GeoVax Labs, Inc. is a biopharmaceutical company focused on developing vaccines and therapies for infectious diseases and cancers. It utilizes its vaccine technology platform to create innovative solutions.